Since I1R and I3R do not share similar ligand‐binding sites and I3R is a regulator of insulin secretion, the potential interaction of rilmenidine with the I3type imidazoline receptor might explain its effects on improved insulin resistance and, thus, glucose levels (Bousquet et al., 2020). The gene discussed is INS; the disease is Insulin resistance.